• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Alternating Glivec and Stivarga Doesn’t Improve Advanced GIST Outcomes

by MM360 Staff | Apr 28, 2025 | Uncategorized

Source: CureToday articles Alternating between Glivec and Stivarga therapy didn’t impact survival outcomes; it led to more toxicity and discontinuations in patients with GIST. Read More

Breast MRI Offers Sensitive Imaging for High-Risk and Diagnosed Patients

by MM360 Staff | Apr 28, 2025 | Uncategorized

Source: CureToday articles Breast MRI helps doctors detect disease in newly diagnosed and high-risk patients without replacing mammograms, according to an expert. Read More

Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer

by MM360 Staff | Apr 28, 2025 | Uncategorized

Source: CureToday articles Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety. Read More

How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer

by MM360 Staff | Apr 28, 2025 | Uncategorized

Source: CureToday articles I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference. Read More

TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups

by MM360 Staff | Apr 28, 2025 | Uncategorized

Source: CureToday articles TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. Read More

Zongertinib Elicits Responses in HER2-Mutant NSCLC

by MM360 Staff | Apr 28, 2025 | Uncategorized

Source: CureToday articles Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
  • Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT